Advicenne
Advicenne is a Paris-based specialty pharmaceutical company developing and commercializing pediatric-friendly treatments for rare renal diseases (Sibnayal® for dRTA) and pediatric epilepsy (Likozam®), serving patients across Europe and the Middle East with FDA review pending in the US.
- Company typePublic
- Founded2017
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Advicenne does
Advicenne is a Paris-based specialty pharmaceutical company founded in 2007 and listed on Euronext Growth Paris (ticker: ALDVI) since March 2022, focused on developing and commercializing treatments for rare kidney diseases and niche pediatric neurology indications. Its lead product, Sibnayal® (ADV7103), is a prolonged-release granule formulation combining potassium citrate and potassium bicarbonate for the treatment of distal Renal Tubular Acidosis (dRTA) in both children and adults. Sibnayal® received European Commission approval in May 2021 and MHRA approval in July 2021, making it the first approved treatment for dRTA in Europe and the UK. The product is commercially available across most of Europe (France, UK, Germany, Denmark, Italy, Spain, Portugal, Nordics) and the Middle East (Saudi Arabia, UAE) through a hybrid model combining direct sales in core markets with exclusive distribution partnerships (FrostPharma AB, Taïba Healthcare, SPA, Avanzanite Bioscience). A second commercial product, Likozam® (clobazam) for drug-resistant pediatric epilepsy, received French reimbursement in June 2026, and a cystinuria indication for ADV7103 is in clinical development with FDA Orphan Drug Designation granted in March 2024.
The company generates revenue through product sales (€5.79 million in 2025, up 18.7% YoY), royalty income from divested/licensed products (€1.1 million in 2025), and licensing agreements, with pricing set via national reimbursement systems. R&D, clinical, and regulatory activities are coordinated from Paris with US operations supporting the FDA NDA process; FDA accepted the Sibnayal® dRTA NDA for review in January 2026 with a decision expected by September 2026. The company holds Orphan Drug Designations from both the EMA and FDA for ADV7103 in dRTA and cystinuria, and has secured over €33 million in cumulative financing through EIB debt tranches, state-guaranteed loans, and equity placements.
Financially, Advicenne is in a critical transition phase: 2025 net loss widened to €9.53 million (from €6.47 million in 2024) due to elevated R&D spending and pharmaceutical taxes, and the year-end 2025 cash position was only €1.35 million. In May 2026 the company opened safeguard proceedings to restructure its liabilities, followed by a €3.8 million bond financing in June 2026 extending cash runway to Q2 2027. Revenue concentration remains moderate, with Sibnayal® as the dominant product and heavy reliance on French and UK reimbursement systems for pricing and access.
Advicenne firmographics
Firmographics- Name
- Advicenne
- Legal name
- Advicenne
- Website
- https://advicenne.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Advicenne is a Paris-based specialty pharmaceutical company developing and commercializing pediatric-friendly treatments for rare renal diseases (Sibnayal® for dRTA) and pediatric epilepsy (Likozam®), serving patients across Europe and the Middle East with FDA review pending in the US.
- Ownership category
- akta.pro rank
Advicenne industry classification
Industry- Product category
- Specialty Pharmaceuticals - Rare Renal Disease Therapeutics
- NAICS
- Kidney Dialysis Centers (621492)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Rare Renal & Nephrology Disorder Therapies (HLAIAIAI)
- akta.pro secondary industries
- Renal Nutrition & Kidney Dietetics Services (HLAKAHAL), Pediatric Nephrology (HLAKAHAH), Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where Advicenne is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
Advicenne business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- Product Sales - Sibnayal®: Direct product sales of Sibnayal® for dRTA treatment across European markets (France, UK, Germany, Denmark, Italy, Spain, Portugal, Nordic countries, Saudi Arabia, UAE). Revenue generated through pharmacy dispensing with official reimbursement in multiple countries.
- Product Sales - Likozam®: Sales of Likozam® (clobazam) for drug-resistant epilepsy in France, with reimbursement from French social security system at €92.24 per 150ml bottle.
- Royalties: Royalty income from licensed products including ADV6209 sold to Primex Pharmaceuticals AG. Royalties doubled to €1.1 million in 2025.
- Out-licensing - Levidcen: License agreement with Desitin for anti-epileptic Levidcen micro-granules for French market.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Likozam® 150ml bottle reimbursement price |
Go-to-market motion3 records
Distribution channels7 records
Marketing channels5 records
Advicenne product offering
Product offeringCore offering
Advicenne develops and commercializes pediatric-friendly specialty pharmaceutical products for rare renal diseases, with lead product Sibnayal® (ADV7103), a prolonged-release granule formulation combining potassium citrate and potassium bicarbonate approved in Europe and the UK for treating distal Renal Tubular Acidosis (dRTA) in children and adults. The portfolio also includes Likozam® (clobazam) for drug-resistant pediatric epilepsy, with pipeline expansion into cystinuria via ADV7103.
Product overview
Advicenne is a specialty pharmaceutical company dedicated to developing and commercializing pediatric-friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The company's primary commercial product is Sibnayal® (ADV7103), a combination of potassium citrate and potassium bicarbonate approved in 2021 for treating distal Renal Tubular Acidosis (dRTA) in Europe and the UK, with FDA review ongoing in the United States. The product portfolio also includes Likozam® (clobazam) for drug-resistant epilepsy in children, which received French reimbursement in 2026. The pipeline includes ADV7103 for cystinuria treatment. The company operates from Paris, France, and is listed on Euronext Growth (ALDVI).
Differentiator
Problem solved
Functional benefit
Brands
- Sibnayal®: Lead product (ADV7103) - combination of Potassium citrate and Potassium bicarbonate for treatment of distal Renal Tubular Acidosis (dRTA). Approved by EMA and MHRA in 2021.
- Likozam®
- Levidcen
Products and services
- Sibnayal® (ADV7103) A prolonged-release granule formulation combining potassium citrate and potassium bicarbonate for the treatment of distal Renal Tubular Acidosis (dRTA) in adults and children. Approved by the European Medicines Agency (2021) and UK MHRA (2021); under FDA review in the United States. Available in 8 mEq and 24 mEq doses.
- Likozam® (clobazam) An anti-epileptic medication (clobazam) primarily used for the treatment of drug-resistant epilepsy in children. Reimbursed in France at €92.24 per 150ml bottle through the French social security system.
- ADV7103 for Cystinuria Pipeline extension of ADV7103 in development for the treatment of cystinuria, a rare inherited cystine transport disorder causing recurrent kidney stones. Granted FDA Orphan Drug Designation in March 2024.
Quantifiable outcome
- European end-market sales of Sibnayal® surged 71% to €10.8 million in 2025
- +3 more outcomes
Companies that use Advicenne
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Advicenne technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Advicenne partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- Primex Pharmaceuticals AGminorAgreement finalized December 2024 for previously sold drug candidate ADV6209 (for moderate sedation). Generates ongoing royalty income.
- Avanzanite BiosciencecoreDistribution agreement completing European commercial coverage of Sibnayal®, specifically for Germany. Finalizes full European geographic footprint.
- SPA (Società Prodotti Antibiotici)coreExclusive distribution agreement for marketing of Sibnayal® in Italy, Spain, and Portugal. Strategic partnership for Southern European market coverage.
- Taïba HealthcarecoreCommercialization agreement for Sibnayal® in Middle-East region. Enables patient access in Saudi Arabia (marketing authorization and reimbursement received July 2025) and UAE (January 2026).
- FrostPharma ABcoreExclusive distribution partnership for commercialization of Sibnayal™ in the Nordic region (Denmark, Norway, Sweden, Finland, Iceland). Enables market access in Nordic countries through established local pharmaceutical distribution.
- Elaiapharm LundbeckcoreLong-term manufacturing supply agreement securing production of ADV7103. Ensures reliable supply chain for commercial production of Sibnayal®.
- European Society for Paediatric Nephrology (ESPN)minorPartnership to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe. Aims to enhance knowledge and management of the disease through scientific collaboration.
- DesitinminorLicense agreement on anti-epileptic Levidcen micro-granules for French market. Product authorized for marketing in France April 2015.
Scale indicators11 records
Recent moves9 records
Expansion highlights5 records
Advicenne competitors and assessment
Company assessmentBroad incumbents
- BioMarin Pharmaceutical: Established US rare disease specialty pharma with a portfolio of orphan therapies across multiple indications. Comparable as a larger, commercially mature rare disease player pursuing similar regulatory and reimbursement pathways.
- Ultragenyx Pharmaceutical: Commercial-stage rare disease biotech with multiple approved orphan therapies and a focus on smaller populations. Comparable in business model, regulatory pathway expertise, and commercial-stage rare disease focus.
- Alexion / AstraZeneca Rare Disease: Global rare disease franchise within AstraZeneca with established renal and metabolic rare disease therapies (e.g., complement-mediated kidney disorders). Comparable as a broader incumbent that overlaps with Advicenne's nephrology rare disease focus.
- Otsuka Pharmaceutical: Established Japanese pharmaceutical company that developed JYNARQUE (tolvaptan) for autosomal dominant polycystic kidney disease (ADPKD). Comparable as a large incumbent with a meaningful rare renal franchise overlapping Advicenne's nephrology focus.
Direct peers
- Travere Therapeutics: US rare-disease specialty pharma with a focused rare kidney disease portfolio (FILSPARI for IgA nephropathy, sparsentan). Comparable to Advicenne as a small-cap rare renal player pursuing orphan indications and navigating similar commercial and regulatory milestones.
- Arbor Pharmaceuticals: US specialty pharmaceutical company with products in nephrology and related therapeutic areas. Comparable as a smaller specialty pharma with focused renal/urology commercial offerings and similar distribution-driven commercial model.
- Calliditas Therapeutics: Swedish specialty pharma that developed Tarpeyo, the first FDA-approved treatment for IgA nephropathy. Highly comparable as a small European-headquartered rare renal disease company commercializing an orphan kidney therapy in the US and EU.
- Swedish Orphan Biovitrum (Sobi): Swedish-headquartered rare disease specialty pharma commercializing across Europe and the US. Comparable in business model (rare disease focus, European-listed, commercial-stage) and in serving similar small-population specialty indications.
- Recordati Rare Diseases: The rare disease division of Recordati, focused on specialty and orphan therapies across multiple geographies. Comparable to Advicenne as a Europe-based specialty pharma commercializing orphan therapeutics via partner-driven distribution.
Emerging players
- Chinook Therapeutics (Novartis): Rare kidney disease biotech (acquired by Novartis in 2023) that developed therapies for IgA nephropathy and other rare renal conditions. Comparable as a focused rare renal disease developer that pursued similar orphan nephrology indications.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Advicenne social profiles
Digital presenceAdvicenne compliance and trust
Trust signalCompliance2 records
Advicenne financial estimates
Financial estimateRevenue estimate
Valuation estimate
Advicenne leadership team
Management profileNumber of profiles
Profiles3 records
Advicenne subsidiaries and ownership
Company hierarchySubsidiaries5 records
Advicenne funding detail
Funding detailFunding overview
Funding rounds7 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Advicenne M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Advicenne
What does Advicenne do?
Advicenne develops and commercializes pediatric-friendly specialty pharmaceutical products for rare renal diseases, with lead product Sibnayal® (ADV7103), a prolonged-release granule formulation combining potassium citrate and potassium bicarbonate approved in Europe and the UK for treating distal Renal Tubular Acidosis (dRTA) in children and adults. The portfolio also includes Likozam® (clobazam) for drug-resistant pediatric epilepsy, with pipeline expansion into cystinuria via ADV7103.
Is Advicenne a public or private company?
Advicenne is a public company. It is classified as public and is currently operating.
When was Advicenne founded?
Advicenne was founded in 2017. It employs 11 to 50 people.
Where is Advicenne based?
Advicenne is headquartered in Paris, France, in the Europe region.
How does Advicenne make money?
Four revenue lines are on record. Product Sales - Sibnayal® is the primary driver. The others are product Sales - Likozam®, royalties and out-licensing - Levidcen.
Who are Advicenne's main competitors?
Broad incumbents on record are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Alexion / AstraZeneca Rare Disease and Otsuka Pharmaceutical. Direct peers are Travere Therapeutics, Arbor Pharmaceuticals, Calliditas Therapeutics, Swedish Orphan Biovitrum (Sobi) and Recordati Rare Diseases. Chinook Therapeutics (Novartis) is listed as an emerging player.
Does Advicenne have an API?
No public API is recorded for Advicenne.
What industry is Advicenne in?
Advicenne's product category is Specialty Pharmaceuticals - Rare Renal Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAI, Rare Renal & Nephrology Disorder Therapies, with a secondary code of HLAKAHAL, Renal Nutrition & Kidney Dietetics Services. Its NAICS code is 621492 and its SIC code is 5122.